253 - Late Breaker Abstract Session: What's Going Viral

Moderator(s)

• 

  Ruth Lynfield, MD (she/her/hers)

  State Epidemiologist and Medical Director
  Minnesota Department of Health
  St. Paul, MN, United States
• 

  C. Mary Healy, MD, FIDSA (she/her/hers)

  Associate Professor of Pediatrics, Infectious Diseases
  Baylor College of Medicine
  Houston, TX, United States

Presentations:

• 1:45 PM – 1:57 PM US PT

  Safety and Immunogenicity of mRNA-1403, a Multivalent Norovirus mRNA Vaccine, in Healthy Adults: Interim Results of a Phase 1/2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Trial
  

  Presenting Author: Till Schoofs, MD – Moderna, Inc

  Co-Author: Brooke A. Bollman, PhD – Moderna, Inc

  Co-Author: Kevin Mancini, MS – Moderna, Inc

  Co-Author: Wenlin Yuan, MS, PhD – Moderna, Inc

  Co-Author: Lauren Bailey, PhD – Moderna, Inc

  Co-Author: Tin Bartholomew, MA – Moderna, Inc

  Co-Author: Esther Levine, MD – Moderna, Inc

  Co-Author: Katherine B. Carlson, PhD, MPH (she/her/hers) – Moderna

  Co-Author: Alexander Rumyantsev, MD, PhD – Moderna, Inc

  Co-Author: Meklit Workneh, MD, MPH – Moderna, Inc

  Co-Author: Doran Fink, MD, PhD – Moderna, Inc

  Co-Author: Jaap Oostendorp, PhD – Moderna, Inc
• 1:57 PM – 2:09 PM US PT

  Chandipura virus infection: Time to think beyond Encephalitis?
  

  Presenting Author: Kathan P. Buch, MBBS – GCS Medical College, Hospital and research centre

  Co-Author: Pankaj M. Buch, MBBS, MD – PDU Medical College, Rajkot, Gujarat
• 2:09 PM – 2:21 PM US PT

  Week 48 Results of a Phase 2 Study Evaluating Once-weekly Oral Islatravir Plus Lenacapavir
  

  Presenting Author: Amy E. Colson – Community Resource Initiative

  Co-Author: Gordon E. Crofoot, n/a – The Crofoot Research Center

  Co-Author: Peter J. Ruane, n/a – Ruane Clinical Research

  Co-Author: Moti N. Ramgopal, n/a – Midway Immunology & Research Center

  Co-Author: Alexandra W. Dretler, n/a – Metro Infectious Disease Consultants

  Co-Author: Ronald G. Nahass, MD – ID Care

  Co-Author: Gary I. Sinclair, n/a – Prism Health North Texas

  Co-Author: Mezgebe Berhe, MD, MPH – North Texas Infectious Diseases Consultants

  Co-Author: Fadi Shihadeh, n/a – Gilead Sciences

  Co-Author: Shan-Yu Liu, PhD – Gilead Sciences Inc

  Co-Author: Stephanie Klopfer, n/a – Merck & Co., Inc.

  Co-Author: Sharline Madera, MD, PhD – Gilead Sciences, Inc.

  Co-Author: Hadas Dvory-Sobol, PhD – Gilead Sciences

  Co-Author: Martin Rhee, MD – Gilead Sciences

  Co-Author: Elizabeth G. Rhee, n/a – Merck & Co., Inc.

  Co-Author: Jared Baeten, MD, PhD – Gilead Sciences

  Co-Author: Joseph J. Eron, MD – University of North Carolina at Chapel Hill School of Medicine
• 2:21 PM – 2:33 PM US PT

  Metformin reduces the risk of Long COVID or Death over 6 months in an Emulated Target Trial of Primarily Omicron-infected Adults without Diabetes or Prediabetes: a New-User, Active-Comparator Analysis Using the National COVID Cohort Collaborative (N3C) Electronic Health Record Database. This research was supported in part by the Intramural/Extramural research program of the National Center for Advancing Translational Science, NIH.
  

  Presenting Author: Carolyn Bramante, MD, MPH – University of Minnesota

  Co-Author: Til Sturmer, MD, PhD – University of North Carolina, Chapel Hill

  Co-Author: Jared Huling, PhD – University of Minnesota

  Co-Author: John Buse, MD, PhD – University of North Carolina, Chapel Hill

  Co-Author: Steve Johnson, PhD – University of Minnesota

  Co-Author: Christopher Lindsell, PhD – Duke University

  Co-Author: Thomas Stewart, PhD – University of Virginia

  Co-Author: David Sahner, MD – National Institute of Health

  Co-Author: Sarah Dunsmore, PhD – National Institute of Health

  Co-Author: Eric Topol, MD, PhD – Scripps Research
• 2:33 PM – 2:45 PM US PT

  Safety and Immunogenicity of Mpox Vaccination in Adolescents
  

  Presenting Author: C. Mary Healy, MD, FIDSA (she/her/hers) – Baylor College of Medicine

  Co-Author: C. Buddy Creech, MD, MPH – Vanderbilt University Medical Center

  Co-Author: Sharon E. Frey, MD – Saint Louis University

  Co-Author: Andrea Lerner, MD – DMID/NIAID/NIH

  Co-Author: Kay Tomashek, M.D – National Institutes of Health

  Co-Author: John H. Beigel, MD – The National Institute of Allergy and Infectious Diseases, National Institutes of Health
• 2:45 PM – 2:57 PM US PT

  Pharmacokinetics (PK) and Safety of Nirmatrelvir/Ritonavir (NMV/r) in Non-Hospitalized Symptomatic Pediatric Patients Ages 6 Years and Older with COVID-19 who are at Increased Risk of Progression to Severe Disease (EPIC-Peds)
  

  Presenting Author: Jacqueline Gerhart, PhD, MBA, MS – Pfizer

  Co-Author: Heidi Leister-Tebbe, BSN (she/her/hers) – Pfizer Inc

  Co-Author: Namita Singh, MD – Pfizer

  Co-Author: Phylinda L. S. Chan, PhD – Pfizer

  Co-Author: Haihong Shi, MS, MBA – Pfizer

  Co-Author: William D H Carey, N/A, MBBS, PhD, MRCPI – Pfizer

  Co-Author: Jean Yan, M.S. – Pfizer Inc., Sanford, Florida, USA

  Co-Author: Mary Lynn Baniecki, PhD – Pfizer Inc

  Co-Author: Victoria Hendrick, BSc – Pfizer

  Co-Author: Wayne Wisemandle, MA – Pfizer Inc

  Co-Author: Ravi Shankar P. Singh, PhD, FCP – Pfizer

  Co-Author: Jennifer Hammond, PhD – Pfizer Inc